SCHEMBL29336928

SCHEMBL29336928

CCOC(=N)c1cccc(Oc2ccc3[nH]ccc3c2C(=O)OC)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 3/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ MAPT P10636 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ F2 P00734 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ BRD4 O60885 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ ICAM1 P05362 1/20 0.37
▸ SELE P16581 1/20 0.37
▸ RHEB Q15382 1/20 0.37
▸ AURKA O14965 1/20 0.36
▸ ELANE P08246 1/20 0.36
▸ SNCA P37840 2/20 0.35
▸ TUBB4A P04350 1/20 0.35
▸ TUBB P07437 1/20 0.35
▸ TUBA3C P0DPH7 1/20 0.35
▸ TUBA1B P68363 1/20 0.35
▸ TUBA4A P68366 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30285642 1.00 F10 (0.40) F10MEN1MAPTKMT2AF2
SCHEMBL29338295 0.92 KDM4E (0.40) F10MAPTKDM4EHSD17B10RHEB
SCHEMBL31176868 0.90 F10 (0.41) F10MEN1MAPTKMT2AF2
SCHEMBL30285551 0.87 L3MBTL1 (0.44) MEN1MAPTKMT2AKDM4EHSD17B10
SCHEMBL29337712 0.87 L3MBTL1 (0.44) MEN1MAPTKMT2AKDM4EHSD17B10
SCHEMBL29338529 0.87 TUBB4A (0.39) F10MAPTBRD4KDM4EHSD17B10
SCHEMBL30285558 0.87 TUBB4A (0.39) F10MAPTBRD4KDM4EHSD17B10
SCHEMBL29336710 0.87 F10 (0.45) F10F2KDM4EHSD17B10
SCHEMBL29338297 0.85 KDM4E (0.38) F10MEN1MAPTKMT2AF2
SCHEMBL29337702 0.80 USP2 (0.43) F10KDM4EHSD17B10RHEBTUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239784-A1 INDOLE COMPOUNDS AND METHODS OF USE GENZYME CORPORATION 2024-07-18 — — US disclosed
US-20240239784-A1 INDOLE COMPOUNDS AND METHODS OF USE GENZYME CORPORATION 2024-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239784-A1 INDOLE COMPOUNDS AND METHODS OF USE CFTR, INMT, IDO1 F10 3750/4885MEN1 2690/4885MAPT 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback